This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donadio, A. C. Articles by Bosl, G. J. Search for Related Content PubMed PubMed Citation Articles by Donadio, A. C. Articles by Bosl, G. J. Social Bookmarking                            What's this?

Chemotherapy for Teratoma With Malignant Transformation

From the Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to George J. Bosl, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: boslg{at}mskcc.org.

Purpose: Teratoma with malignant transformation (MT) is a well-described entity that refers to the MT of a somatic teratomatous component in a germ cell tumor (GCT) to a histology that is identical to a somatic malignancy (eg, rhabdomyosarcoma [RMS]). Surgical resection has been the mainstay of therapy for localized transformed disease because these tumors are thought to be resistant to standard treatment. We report that chemotherapy has a role in selected patients with MT, determined by cell type.

Patients and Methods: Chemotherapy was administered to 12 patients with MT of GCT limited to a single cell type (two patients with primitive neuroectodermal tumors, five with undifferentiated RMS, one with anaplastic small-cell tumor, two with adenocarcinoma, and two with leukemia); 10 patients had measurable disease. GCT origin was confirmed by molecular cytogenetics in five patients. Each patient received chemotherapy regimens based on the specific malignant cell observed in the transformed histology.

Results: Seven patients with measurable disease achieved a partial response, with the duration of response ranging between 1 month and 7 years. Three of those patients are alive. Three patients did not respond to treatment, and all of those patients died as a result of their disease.

Conclusion: Chemotherapy for MT limited to a single cell type may result in major responses and long-term survival in selected patients. Local therapy after chemotherapy is an important component of treatment to achieve maximum response.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. J. Lavery, R. R. Bahnson, D. S. Sharp, and K. S. Pohar Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors Therapeutic Advances in Urology, October 1, 2009; 1(4): 199 - 207. [Abstract] [PDF]

				C. Chen, H. Zheng, and S. Jiang An Unusual Case of Giant Mediastinal Teratoma With Malignant Transformation Ann. Thorac. Surg., July 1, 2008; 86(1): 302 - 304. [Abstract] [Full Text] [PDF]

				K. Fizazi, J. Oldenburg, A. Dunant, I. Chen, R. Salvioni, J. T. Hartmann, M. De Santis, G. Daugaard, A. Flechon, U. de Giorgi, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study Ann. Onc., February 1, 2008; 19(2): 259 - 264. [Abstract] [Full Text] [PDF]

				B. S. Carver, B. Shayegan, A. Serio, R. J. Motzer, G. J. Bosl, and J. Sheinfeld Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma J. Clin. Oncol., March 20, 2007; 25(9): 1033 - 1037. [Abstract] [Full Text] [PDF]

				L. H. Einhorn Role of the Urologist in Metastatic Testicular Cancer J. Clin. Oncol., March 20, 2007; 25(9): 1024 - 1025. [Full Text] [PDF]

				B. V. Duwe, D. H. Sterman, and A. I. Musani Tumors of the Mediastinum Chest, October 1, 2005; 128(4): 2893 - 2909. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta, J. Bacik, A. Donadio, D. Bajorin, S. Marion, J. Sheinfeld, G. J. Bosl, and R. J. Motzer Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors J. Clin. Oncol., September 20, 2005; 23(27): 6549 - 6555. [Abstract] [Full Text] [PDF]

				O. Rick, C. Bokemeyer, S. Weinknecht, J. Schirren, T. Pottek, J.T. Hartmann, T. Braun, B. Rachud, L. Weissbach, M. Hartmann, et al. Residual Tumor Resection After High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Cancer J. Clin. Oncol., September 15, 2004; 22(18): 3713 - 3719. [Abstract] [Full Text] [PDF]